Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes

Anderson, 2011, Circulation, 123, e426, 10.1161/CIR.0b013e318212bb8b Angiolillo, 2011, A pharmacodynamic comparison of prasugrel vs high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing Anti-Platelet Therapy in Diabetes Mellitus (OPTIMUS)-3 trial, Eur Heart J, 32, 838, 10.1093/eurheartj/ehq494 Angiolillo, 2010, Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease on dual antiplatelet therapy, J Am Coll Cardiol, 55, 1139, 10.1016/j.jacc.2009.10.043 Angiolillo, 2006, Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment, J Am Coll Cardiol, 48, 298, 10.1016/j.jacc.2006.03.038 Angiolillo, 2011, Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy, Thromb Haemost, 106, 253, 10.1160/TH11-01-0041 Angiolillo, 2010, Platelet thrombin receptor antagonism and atherothrombosis, Eur Heart J, 31, 17, 10.1093/eurheartj/ehp504 Angiolillo, 2008, A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study, Eur Heart J, 29, 2202, 10.1093/eurheartj/ehn287 Angiolillo, 2005, Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment, Diabetes, 54, 2430, 10.2337/diabetes.54.8.2430 Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741 1994, Collaborative overview of randomised trials of antiplatelet therapy: I, BMJ, 308, 81, 10.1136/bmj.308.6921.81 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 Bartnik, 2004, The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart, Eur Heart J, 25, 1880, 10.1016/j.ehj.2004.07.027 Bertrand, 2000, Circulation, 102, 624, 10.1161/01.CIR.102.6.624 Bhatt, 2002, Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus, Am J Cardiol, 90, 625, 10.1016/S0002-9149(02)02567-5 Biondi-Zoccai, 2008, Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention, Am Heart J, 155, 1081, 10.1016/j.ahj.2007.12.024 Cadroy, 2000, Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans, Circulation, 101, 2823, 10.1161/01.CIR.101.24.2823 Capodanno, 2011, Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease, Circ Cardiovasc Interv, 4, 180, 10.1161/CIRCINTERVENTIONS.110.960187 Colwell, 2004, Aspirin therapy in diabetes, Diabetes Care, 27, S72 DiChiara, 2007, The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the Aspirin-Induced Platelet Effect (ASPECT) study, Diabetes, 56, 3014, 10.2337/db07-0707 Ferreiro, 2009, Clopidogrel response variability: Current status and future directions, Thromb Haemost, 102, 7, 10.1160/TH09-03-0185 Ferreiro, 2011, Diabetes and antiplatelet therapy in acute coronary syndrome, Circulation, 123, 798, 10.1161/CIRCULATIONAHA.109.913376 Ferreiro, 2011, Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus, Rev Esp Cardiol Gurbel, 2007, Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study, Circulation, 115, 3156, 10.1161/CIRCULATIONAHA.106.675587 Guthikonda, 2007, Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin, J Thromb Haemost, 5, 490, 10.1111/j.1538-7836.2007.02387.x James, 2010, Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATELET Inhibition and Patient Outcomes (PLATO) trial, Eur Heart J, 31, 3006, 10.1093/eurheartj/ehq325 Kushner, 2009, Circulation, 120, 2271, 10.1161/CIRCULATIONAHA.109.192663 Mehta, 2010, Dose comparisons of clopidogrel and aspirin in acute coronary syndromes, N Engl J Med, 363, 930, 10.1056/NEJMoa0909475 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Patrono, 2005, Low-dose aspirin for the prevention of atherothrombosis, N Engl J Med, 353, 2373, 10.1056/NEJMra052717 Pignone, 2010, Aspirin for primary prevention of cardiovascular events in people with diabetes, J Am Coll Cardiol, 55, 2878, 10.1016/j.jacc.2010.04.003 Price, 2011, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial, JAMA, 305, 1097, 10.1001/jama.2011.290 Sabatine, 2005, Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study, JAMA, 294, 1224, 10.1001/jama.294.10.1224 Snoep, 2007, Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis, Arch Intern Med, 167, 1593, 10.1001/archinte.167.15.1593 Steinhubl, 2002, Clopidogrel for the reduction of events during observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, JAMA, 288, 2411, 10.1001/jama.288.19.2411 Storey, 2007, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes, J Am Coll Cardiol, 50, 1852, 10.1016/j.jacc.2007.07.058 Ueno, 2011, Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel, JACC Cardiovasc Interv, 4, 905, 10.1016/j.jcin.2011.05.016 Webster, 1997, What cardiologists need to know about diabetes, Lancet, 350, S23, 10.1016/S0140-6736(97)90025-8 Wild, 2004, Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Wittkowsky, 2010, New oral anticoagulants: A practical guide for clinicians, J Thromb Thrombolysis, 29, 182, 10.1007/s11239-009-0409-0 Wiviott, 2008, Circulation, 118, 1626, 10.1161/CIRCULATIONAHA.108.791061 Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746